The use of molecular diagnostics in bladder cancer

Urologic Oncology

Volumn 5, Issue 3, 2000, Pages 87-92

  Han, Misop ^a   Schoenberg, Mark P ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Bladder neoplasms; Transitional cell; Tumor markers

Indexed keywords

BIOCHEMICAL MARKER; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

BLADDER CANCER; COST BENEFIT ANALYSIS; CYSTOSCOPY; FLOW CYTOMETRY; HUMAN; MEDICINE; MITOSIS; MOLECULAR BIOLOGY; PRIORITY JOURNAL; REVIEW; TELOMERE; TRANSITIONAL CELL CARCINOMA;

EID: 0034607404     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(99)00052-6     Document Type: Review

References (46)

1. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics, 1998. CA Cancer J Clin. 48(1):1998;6-29. [published errata appear in CA Cancer J Clin 1998 May-Jun;48(3):192 and 1998 Nov-Dec;48(6):329].
2. Abel P.D. Prognostic indices in transitional cell carcinoma of the bladder. Br J Urol. 62(2):1998;103-109.
3. Lutzeyer W., Rubben H., Dahm H. Prognostic parameters in superficial bladder cancer. an analysis of 315 cases J Urol. 127(2):1982;250-252.
4. Papanicolaou G., Marshall V. Urine sediment smears as a diagnostic procedure in cancers of the urinary tract. Science. 101(2629):1945;519-520.
5. Gamarra M.C., Zein T. Cytologic spectrum of bladder cancer. Urology. 23(3 suppl):1984;23-26.
6. Badalament R.A., Hermansen D.K., Kimmel M.et al. The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer. 60(7):1987;1423-1427.
7. Sarosdy M.F., deVere White R.W., Soloway M.S.et al. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol. 154(2 Pt 1):1995;379-384.
8. Leyh H., Mazeman E. Bard BTA test compared with voided urine cytology in the diagnosis of recurrent bladder cancer. Eur Urol. 32(4):1997;425-428.
9. D'Hallewin M.A., Baert L. Initial evaluation of the bladder tumor antigen test in superficial bladder cancer. J Urol. 155(2):1996;475-476. [published erratum appears in J Urol 1996 Jun;155(6):2041].
10. Ianari A., Sternberg C.N., Rossetti A.et al. Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder. Urology. 49(5):1997;786-789.
11. Leyh H., Hall R., Mazeman E., Blumenstein B.A. Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder. Urology. 50(1):1997;49-53.
12. Ellis W.J., Blumenstein B.A., Ishak L.M., Enfield D.L. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group. Urology. 50(6):1997;882-887.
13. Kinders R., Jones T., Root R.et al. Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res. 4(10):1998;2511-2520.
14. Sarosdy M.F., Hudson M.A., Ellis W.J.et al. Improved detection of recurrent bladder cancer using the Bard BTA stat test. Urology. 50(3):1997;349-353.
15. McCabe R.P., Lamm D.L., Haspel M.V.et al. A diagnostic-prognostic test for bladder cancer using a monoclonal antibody-based enzyme-linked immunoassay for detection of fibrin(ogen) degradation products. Cancer Res. 44:1984;5886-5893.
16. Wajsman Z., Merrin C.E., Chu T.M., Moore R.H., Murphy G.P. Evaluation of biological markers in bladder cancer. J Urol. 114(6):1975;879-893.
17. Wajsman Z., Williams P.D., Greco J., Murphy G.P. Further study of fibrinogen degradation products in bladder cancer detection. Urology. 12(6):1978;659-661.
18. Schmetter B.S., Habicht K.K., Lamm D.L.et al. A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J Urol. 158(3 Pt 1):1997;801-805.
19. Johnston B., Morales A., Emerson L., Lundie M. Rapid detection of bladder cancer. a comparative study of point of care tests J Urol. 158(6):1997;2098-2101.
20. Keesee S.K., Briggman J.V., Thill G., Wu Y.J. Utilization of nuclear matrix proteins for cancer diagnosis. Crit Rev Eukaryot Gene Expr. 6(2-3):1996;189-214.
21. Carpinito G.A., Stadler W.M., Briggman J.V.et al. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol. 156(4):1996;1280-1285.
22. Zippe C., Pandrangi L., Agarwal A. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer. J Urol. 161(1):1999;62-65.
23. Landman J., Chang Y., Kavaler E., Droller M.J., Liu B.C. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology. 52(3):1998;398-402.
24. Del Nero A., Esposito N., Curro A.et al. Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer. comparison with urinary cytology and BTA test Eur Urol. 35(2):1999;93-97.
25. Soloway M.S., Briggman V., Carpinito G.A.et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol. 156(2 Pt 1):1996;363-367.
26. Stampfer D.S., Carpinito G.A., Rodriguez-Villanueva J.et al. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder. J Urol. 159(2):1998;394-398. [published erratum appears in J Urol 1998 May;159(5):1650].
27. Irani J., Desgrandchamps F., Millet C.et al. BTA stat and BTA TRAK. a comparative evaluation of urine testing for the diagnosis of transitional cell carcinoma of the bladder Eur Urol. 35(2):1999;89-92.
28. Giella J.G., Ring K., Olsson C.A., Karp F.S., Benson M.C. The predictive value of flow cytometry and urinary cytology in the followup of patients with transitional cell carcinoma of the bladder. J Urol. 148(2 Pt 1):1992;293-296.
29. Murphy W.M., Emerson L.D., Chandler R.W., Moinuddin S.M., Soloway M.S. Flow cytometry versus urinary cytology in the evaluation of patients with bladder cancer. J Urol. 136(4):1986;815-819.
30. Cowan D.F., Wu B., Young G.P., Khanna O.P. Correlation of histopathological, cytological and flow cytometric findings in neoplastic and nonneoplastic lesions of the bladder. J Urol. 138(4):1987;753-757.
31. Gregoire M., Fradet Y., Meyer F.et al. Diagnostic accuracy of urinary cytology, and deoxyribonucleic acid flow cytometry and cytology on bladder washings during followup for bladder tumors. J Urol. 157(5):1997;1660-1664.
32. Kim N.W., Piatyszek M.A., Prowse K.R.et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 266(5193):1994;2011-2015.
33. Yoshida K., Sugino T., Tahara H.et al. Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer. 79(2):1997;362-369.
34. Rahat M.A., Lahat N., Gazawi H.et al. Telomerase activity in patients with transitional cell carcinoma. a preliminary study Cancer. 85(4):1999;919-924.
35. Yokota K., Kanda K., Inoue Y., Kanayama H., Kagawa S. Semi-quantitative analysis of telomerase activity in exfoliated human urothelial cells and bladder transitional cell carcinoma. Br J Urol. 82(5):1998;727-732.
36. Kavaler E., Landman J., Chang Y., Droller M.J., Liu B.C. Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer. 82(4):1998;708-714.
37. Ramakumar S., Bhuiyan J., Besse J.A.et al. Comparison of screening methods in the detection of bladder cancer. J Urol. 161(2):1999;388-394.
38. Mao L., Lee D.J., Tockman M.S., Erozan Y.S., Askin F., Sidransky D. Microsatellite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci USA. 91(21):1994;9871-9875.
39. Mao L., Schoenberg M.P., Scicchitano M.et al. Molecular detection of primary bladder cancer by microsatellite analysis. Science. 271(5249):1996;659-662.
40. Mourah S., Cussenot O., Vimont V.et al. Assessment of microsatellite instability in urine in the detection of transitional-cell carcinoma of the bladder. Int J Cancer. 79(6):1998;629-633.
41. Sheinfeld J., Reuter V.E., Melamed M.R.et al. Enhanced bladder cancer detection with the Lewis X antigen as a marker of neoplastic transformation. J Urol. 143(2):1990;285-288.
42. Pode D., Golijanin D., Sherman Y., Lebensart P., Shapiro A. Immunostaining of Lewis X in cells from voided urine, cytopathology and ultrasound for noninvasive detection of bladder tumors. J Urol. 159(2):1998;389-393.
43. Mian C., Pycha A., Wiener H., Haitel A., Lodde M., Marberger M. Immunocyt. a new tool for detecting transitional cell cancer of the urinary tract J Urol. 161(5):1999;1486-1489.
44. Lokeshwar V.B., Obek C., Soloway M.S., Block N.L. Tumor-associated hyaluronic acid. a new sensitive and specific urine marker for bladder cancer Cancer Res. 57(4):1997;773-777. [published erratum appears in Cancer Res 1998 Jul 15;58(14):3191].
45. Pham H.T., Block N.L., Lokeshwar V.B. Tumor-derived hyaluronidase. a diagnostic urine marker for high-grade bladder cancer Cancer Res. 57(4):1997;778-783. [published erratum appears in Cancer Res 1997 Apr 15;57(8):1622].
46. Halachmi S., Enger C., Rosenthal D., Sidransky D., Schoenberg M. Molecular diagnosis and staging of bladder cancer. Molecular Urology. 1(4):1997;309-314.